Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.35
A's Cash-to-Debt is ranked lower than
62% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. A: 1.35 )
Ranked among companies with meaningful Cash-to-Debt only.
A' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 1.25 Max: No Debt
Current: 1.35
0.63
No Debt
Equity-to-Asset 0.52
A's Equity-to-Asset is ranked lower than
65% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. A: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
A' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.51 Max: 0.71
Current: 0.52
0.31
0.71
Debt-to-Equity 0.47
A's Debt-to-Equity is ranked lower than
60% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. A: 0.47 )
Ranked among companies with meaningful Debt-to-Equity only.
A' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.43 Max: 1.31
Current: 0.47
0
1.31
Debt-to-EBITDA 1.90
A's Debt-to-EBITDA is ranked lower than
51% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. A: 1.90 )
Ranked among companies with meaningful Debt-to-EBITDA only.
A' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.59  Med: 2.1 Max: 11.3
Current: 1.9
1.59
11.3
Interest Coverage 11.06
A's Interest Coverage is ranked lower than
67% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. A: 11.06 )
Ranked among companies with meaningful Interest Coverage only.
A' s Interest Coverage Range Over the Past 10 Years
Min: 0.53  Med: 8.23 Max: 12.45
Current: 11.06
0.53
12.45
Piotroski F-Score: 7
Altman Z-Score: 4.30
Beneish M-Score: -2.81
WACC vs ROIC
11.41%
5.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 18.93
A's Operating Margin % is ranked higher than
88% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. A: 18.93 )
Ranked among companies with meaningful Operating Margin % only.
A' s Operating Margin % Range Over the Past 10 Years
Min: 1.05  Med: 13.9 Max: 18.93
Current: 18.93
1.05
18.93
Net Margin % 4.25
A's Net Margin % is ranked higher than
65% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. A: 4.25 )
Ranked among companies with meaningful Net Margin % only.
A' s Net Margin % Range Over the Past 10 Years
Min: -0.69  Med: 11.5 Max: 16.81
Current: 4.25
-0.69
16.81
ROE % 4.33
A's ROE % is ranked higher than
61% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. A: 4.33 )
Ranked among companies with meaningful ROE % only.
A' s ROE % Range Over the Past 10 Years
Min: -1.22  Med: 14.46 Max: 26.86
Current: 4.33
-1.22
26.86
ROA % 2.37
A's ROA % is ranked higher than
63% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. A: 2.37 )
Ranked among companies with meaningful ROA % only.
A' s ROA % Range Over the Past 10 Years
Min: -0.41  Med: 7.36 Max: 11.77
Current: 2.37
-0.41
11.77
ROC (Joel Greenblatt) % 77.39
A's ROC (Joel Greenblatt) % is ranked higher than
90% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. A: 77.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
A' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 7.7  Med: 51.72 Max: 78.93
Current: 77.39
7.7
78.93
3-Year Revenue Growth Rate -12.80
A's 3-Year Revenue Growth Rate is ranked lower than
51% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. A: -12.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
A' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.5  Med: -3.1 Max: 14.8
Current: -12.8
-18.5
14.8
3-Year EBITDA Growth Rate -0.30
A's 3-Year EBITDA Growth Rate is ranked higher than
62% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. A: -0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
A' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -12.3 Max: 76.6
Current: -0.3
0
76.6
3-Year EPS without NRI Growth Rate 44.90
A's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. A: 44.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
A' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37.7 Max: 135.6
Current: 44.9
0
135.6
GuruFocus has detected 3 Warning Signs with Agilent Technologies Inc A.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» A's 30-Y Financials

Financials (Next Earnings Date: 2018-05-22)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

A Guru Trades in Q2 2017

Paul Tudor Jones 13,077 sh (+44.13%)
Steven Cohen 1,306,668 sh (+31.16%)
PRIMECAP Management 5,057,020 sh (+6.11%)
Ron Baron 28,000 sh (unchged)
Jim Simons Sold Out
Pioneer Investments Sold Out
Vanguard Health Care Fund 1,667,550 sh (-11.74%)
Mario Gabelli 145,400 sh (-11.88%)
Columbia Wanger 330,675 sh (-46.82%)
Joel Greenblatt 28,923 sh (-56.95%)
» More
Q3 2017

A Guru Trades in Q3 2017

Jeremy Grantham 25,900 sh (New)
Ken Fisher 9,493 sh (New)
Jim Simons 557,700 sh (New)
Caxton Associates 3,500 sh (New)
Joel Greenblatt 45,934 sh (+58.81%)
Paul Tudor Jones 20,704 sh (+58.32%)
Ron Baron 28,000 sh (unchged)
Steven Cohen Sold Out
PRIMECAP Management 4,889,900 sh (-3.30%)
Vanguard Health Care Fund 1,486,550 sh (-10.85%)
Columbia Wanger 285,901 sh (-13.54%)
Mario Gabelli 117,400 sh (-19.26%)
» More
Q4 2017

A Guru Trades in Q4 2017

Pioneer Investments 200,631 sh (New)
Steve Mandel 3,607,622 sh (New)
Leucadia National 24,587 sh (New)
Julian Robertson 286,000 sh (New)
Eaton Vance Worldwide Health Sciences Fund 153,849 sh (New)
Joel Greenblatt 259,354 sh (+464.62%)
Jeremy Grantham 126,100 sh (+386.87%)
Jim Simons 2,370,200 sh (+325.00%)
Paul Tudor Jones 44,531 sh (+115.08%)
Ron Baron 28,000 sh (unchged)
Caxton Associates Sold Out
Columbia Wanger Sold Out
PRIMECAP Management 4,804,100 sh (-1.75%)
Vanguard Health Care Fund 1,423,050 sh (-4.27%)
Ken Fisher 7,749 sh (-18.37%)
Mario Gabelli 57,100 sh (-51.36%)
» More
Q1 2018

A Guru Trades in Q1 2018

Ken Fisher Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Sold Out $65.05 - $74.82 $ 65.80-6%0
Steve Mandel 2017-12-31 New Buy1.26%$64.87 - $70.59 $ 65.80-2%3,607,622
Vanguard Health Care Fund 2017-12-31 Reduce -4.27%0.01%$64.87 - $70.59 $ 65.80-2%1,423,050
Julian Robertson 2017-12-31 New Buy2.99%$64.87 - $70.59 $ 65.80-2%286,000
Joel Greenblatt 2017-12-31 Add 464.62%0.21%$64.87 - $70.59 $ 65.80-2%259,354
Mario Gabelli 2017-12-31 Reduce -51.36%0.03%$64.87 - $70.59 $ 65.80-2%57,100
Leucadia National 2017-12-31 New Buy0.13%$64.87 - $70.59 $ 65.80-2%24,587
Ken Fisher 2017-12-31 Reduce -18.37%$64.87 - $70.59 $ 65.80-2%7,749
Vanguard Health Care Fund 2017-09-30 Reduce -10.85%0.02%$58.57 - $66.17 $ 65.806%1,486,550
Mario Gabelli 2017-09-30 Reduce -19.26%0.01%$58.57 - $66.17 $ 65.806%117,400
Joel Greenblatt 2017-09-30 Add 58.81%0.01%$58.57 - $66.17 $ 65.806%45,934
Ken Fisher 2017-09-30 New Buy$58.57 - $66.17 $ 65.806%9,493
Vanguard Health Care Fund 2017-06-30 Reduce -11.74%0.03%$52.33 - $60.81 $ 65.8016%1,667,550
Mario Gabelli 2017-06-30 Reduce -11.88%0.01%$52.33 - $60.81 $ 65.8016%145,400
Joel Greenblatt 2017-06-30 Reduce -56.95%0.03%$52.33 - $60.81 $ 65.8016%28,923
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3825
Compare:NYSE:IQV, TSE:6869, XSWX:LONN, NAS:IDXX, NYSE:LH, NYSE:DGX, XPAR:ERF, SZSE:300676, XTER:SRT3, XPAR:BIM, NYSE:PKI, XAMS:PHIA, NYSE:BIO, NYSE:QGEN, NAS:ICLR, NAS:DXCM, XTER:AFX, NAS:PRAH, NAS:EXAS, NYSE:CRL » details
Traded in other countries:AG8.Germany,
Headquarter Location:USA
Agilent Technologies Inc is engaged in life sciences, diagnostics and applied chemical markets. The company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow.

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading health-care firm. Today, Agilent's measurement technologies serve a broad base of customers within three operating segments: life science and applied equipment (49% of sales), cross lab (which includes consumables and services at 34%), and diagnostics and genomics (17%). The United States and Europe account for 34% and 27% of revenue, respectively, with China and Japan accounting for the majority of remaining sales. Agilent is headquartered in California.

Top Ranked Articles about Agilent Technologies Inc

Tiger Management Buys eBay, IQVIA, Comcast Firm's largest buys of the 4th quarter
Tiger Management was founded by Julian Robertson (Trades, Portfolio) in 1980. The firm increased several holdings and established many other positions in the fourth quarter. Read more...
Steve Mandel Takes an Interest in IQVIA Holdings Hedge fund releases 4th-quarter portfolio
Lone Pine Capital founder Steve Mandel (Trades, Portfolio) disclosed his fourth-quarter portfolio on Feb. 14, listing eight new positions. Read more...
Investor Expectations to Drive Momentum within Easterly Government Properties, Terreno Realty, Hilton Grand Vacations, Agilent Technologies, Maxim Integrated Products, and MetLife — Discovering Underlying Factors of Influence
Eaton Vance Worldwide Health Sciences Fund Starts 3 Positions in 4th Quarter Fund reports quarterly portfolio
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) primarily invests in companies engaged in the discovery, development, production or distribution of products and services related to scientific advances in health care. Read more...
Investor Expectations to Drive Momentum within Agilent Technologies, Maxim Integrated Products, MetLife, Easterly Government Properties, Terreno Realty, and Hilton Grand Vacations — Discovering Underlying Factors of Influence
Market Trends Toward New Normal in Domino's Pizza, Sangamo Therapeutics, Entergy, Agilent Technologies, Zayo Group, and Republic Services – Emerging Consolidated Expectations, Analyst Ratings
5 Companies Reach 52-Week Highs Synopsys, PG&E, Agilent, Procter & Gamble, McDonald's prices climb
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
PE Ratio 111.53
A's PE Ratio is ranked lower than
94% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. A: 111.53 )
Ranked among companies with meaningful PE Ratio only.
A' s PE Ratio Range Over the Past 10 Years
Min: 5.2  Med: 17.36 Max: 126.81
Current: 111.53
5.2
126.81
Forward PE Ratio 24.94
A's Forward PE Ratio is ranked lower than
65% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. A: 24.94 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 111.53
A's PE Ratio without NRI is ranked lower than
94% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. A: 111.53 )
Ranked among companies with meaningful PE Ratio without NRI only.
A' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.2  Med: 17.92 Max: 301.43
Current: 111.53
5.2
301.43
Price-to-Owner-Earnings 28.57
A's Price-to-Owner-Earnings is ranked higher than
62% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. A: 28.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
A' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.28  Med: 16.94 Max: 247.44
Current: 28.57
6.28
247.44
PB Ratio 4.70
A's PB Ratio is ranked lower than
56% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. A: 4.70 )
Ranked among companies with meaningful PB Ratio only.
A' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 2.79 Max: 5.34
Current: 4.7
1.22
5.34
PS Ratio 4.64
A's PS Ratio is ranked lower than
59% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. A: 4.64 )
Ranked among companies with meaningful PS Ratio only.
A' s PS Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.89 Max: 5.28
Current: 4.64
0.59
5.28
Price-to-Free-Cash-Flow 27.36
A's Price-to-Free-Cash-Flow is ranked lower than
51% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. A: 27.36 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
A' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 15.69 Max: 74.96
Current: 27.36
5.4
74.96
Price-to-Operating-Cash-Flow 21.72
A's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. A: 21.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
A' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.31  Med: 12.85 Max: 41.4
Current: 21.72
4.31
41.4
EV-to-EBIT 22.21
A's EV-to-EBIT is ranked higher than
53% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. A: 22.21 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.6  Med: 14.8 Max: 82.7
Current: 22.21
5.6
82.7
EV-to-EBITDA 18.13
A's EV-to-EBITDA is ranked higher than
52% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. A: 18.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
A' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 11.2 Max: 30.6
Current: 18.13
4.4
30.6
EV-to-Revenue 4.44
A's EV-to-Revenue is ranked lower than
55% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. A: 4.44 )
Ranked among companies with meaningful EV-to-Revenue only.
A' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.7  Med: 1.9 Max: 5.1
Current: 4.44
0.7
5.1
Shiller PE Ratio 35.59
A's Shiller PE Ratio is ranked higher than
69% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. A: 35.59 )
Ranked among companies with meaningful Shiller PE Ratio only.
A' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.84  Med: 21.58 Max: 46.42
Current: 35.59
9.84
46.42
Current Ratio 3.23
A's Current Ratio is ranked higher than
61% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. A: 3.23 )
Ranked among companies with meaningful Current Ratio only.
A' s Current Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.57 Max: 4.08
Current: 3.23
1.61
4.08
Quick Ratio 2.78
A's Quick Ratio is ranked higher than
60% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. A: 2.78 )
Ranked among companies with meaningful Quick Ratio only.
A' s Quick Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.07 Max: 3.44
Current: 2.78
0.99
3.44
Days Inventory 98.63
A's Days Inventory is ranked lower than
57% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. A: 98.63 )
Ranked among companies with meaningful Days Inventory only.
A' s Days Inventory Range Over the Past 10 Years
Min: 91.25  Med: 98.95 Max: 147.41
Current: 98.63
91.25
147.41
Days Sales Outstanding 59.38
A's Days Sales Outstanding is ranked higher than
59% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. A: 59.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.45  Med: 50.26 Max: 59.38
Current: 59.38
47.45
59.38
Days Payable 50.56
A's Days Payable is ranked lower than
63% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. A: 50.56 )
Ranked among companies with meaningful Days Payable only.
A' s Days Payable Range Over the Past 10 Years
Min: 43.61  Med: 51.18 Max: 72.45
Current: 50.56
43.61
72.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.86
A's Dividend Yield % is ranked lower than
53% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. A: 0.86 )
Ranked among companies with meaningful Dividend Yield % only.
A' s Dividend Yield % Range Over the Past 10 Years
Min: 0.31  Med: 1.09 Max: 1.42
Current: 0.86
0.31
1.42
Dividend Payout Ratio 0.92
A's Dividend Payout Ratio is ranked lower than
73% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. A: 0.92 )
Ranked among companies with meaningful Dividend Payout Ratio only.
A' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.09  Med: 0.32 Max: 0.92
Current: 0.92
0.09
0.92
Forward Dividend Yield % 0.89
A's Forward Dividend Yield % is ranked lower than
56% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. A: 0.89 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.24
A's 5-Year Yield-on-Cost % is ranked lower than
54% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. A: 1.24 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
A' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.45  Med: 1.57 Max: 2.05
Current: 1.24
0.45
2.05
3-Year Average Share Buyback Ratio 1.30
A's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. A: 1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
A' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.5  Med: 1.2 Max: 11.4
Current: 1.3
-2.5
11.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 96.76
A's Price-to-Net-Current-Asset-Value is ranked lower than
99% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. A: 96.76 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
A' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.8  Med: 12.69 Max: 1364
Current: 96.76
2.8
1364
Price-to-Tangible-Book 13.71
A's Price-to-Tangible-Book is ranked lower than
81% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. A: 13.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
A' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1  Med: 3.91 Max: 15.31
Current: 13.71
1.1
15.31
Price-to-Intrinsic-Value-Projected-FCF 2.03
A's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
52% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. A: 2.03 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
A' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.6  Med: 1.18 Max: 3.73
Current: 2.03
0.6
3.73
Price-to-Median-PS-Value 2.46
A's Price-to-Median-PS-Value is ranked lower than
90% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. A: 2.46 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
A' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.87 Max: 2.74
Current: 2.46
0.38
2.74
Price-to-Graham-Number 8.25
A's Price-to-Graham-Number is ranked lower than
95% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. A: 8.25 )
Ranked among companies with meaningful Price-to-Graham-Number only.
A' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.84  Med: 2.04 Max: 9.54
Current: 8.25
0.84
9.54
Earnings Yield (Greenblatt) % 4.50
A's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. A: 4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
A' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 6.7 Max: 17.7
Current: 4.5
1.2
17.7
Forward Rate of Return (Yacktman) % -3.81
A's Forward Rate of Return (Yacktman) % is ranked lower than
54% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. A: -3.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
A' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.9  Med: 18.8 Max: 36.5
Current: -3.81
-7.9
36.5

More Statistics

Revenue (TTM) (Mil) $4,616.00
EPS (TTM) $ 0.59
Beta1.53
Volatility18.62%
52-Week Range $53.91 - 75.00
Shares Outstanding (Mil)322.48

Analyst Estimate

Oct18 Oct19 Oct20
Revenue (Mil $) 4,899 5,192 5,488
EBIT (Mil $) 946 1,074
EBITDA (Mil $) 1,179 1,287 1,417
EPS ($) 2.67 2.94 3.23
EPS without NRI ($) 2.67 2.94 3.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.33%
Dividends per Share ($) 0.60 0.66 0.66

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}